David Rolfe Wedgewood Partners
David Rolfe is the chief investment officer of Wedgewood Partners, known for a concentrated growth portfolio of large-capitalization companies. The firm emphasizes quality franchises, high returns on capital, and limited diversification across only a few dozen names at most. Rolfe’s commentaries are followed by investors who prefer focused growth ownership over broad index replication.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$342M |
| 2 |
Cognizant
CTSH
|
+$253M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$247M |
| 4 |
Qualcomm
QCOM
|
+$235M |
| 5 |
EMC
EMC CORPORATION
EMC
|
+$219M |
Top Sells
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.83% |
| 2 | Financials | 18.57% |
| 3 | Healthcare | 17.36% |
| 4 | Industrials | 12.66% |
| 5 | Consumer Discretionary | 7.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$4.51T
| $315M | 9.09% |
+22,216,292
| New | +$342M |
|
|
2
Berkshire Hathaway Class B
BRK.B
$1.06T
| $252M | 7.27% |
+2,248,214
| New | +$247M |
|
|
3
Cognizant
CTSH
$27.9B
| $238M | 6.89% |
+7,614,730
| New | +$253M |
|
|
4
Qualcomm
QCOM
$169B
| $225M | 6.51% |
+3,690,177
| New | +$235M |
|
|
EMC
5
DELISTED
EMC CORPORATION
EMC
| $220M | 6.35% |
+9,303,186
| New | +$219M |
|
|
ESRX
6
DELISTED
Express Scripts Holding Company
ESRX
| $210M | 6.08% |
+3,408,739
| New | +$205M |
|
7
Alphabet (Google) Class C
GOOG
$4.18T
| $188M | 5.43% |
+8,580,160
| New | +$181M |
|
8
Cummins
CMI
$80.9B
| $156M | 4.51% |
+1,440,711
| New | +$163M |
|
|
SCHW
9
Charles Schwab
SCHW
$194B
| $151M | 4.37% |
+7,135,138
| New | +$132M |
|
10
Tapestry
TPR
$26B
| $150M | 4.33% |
+2,624,036
| New | +$148M |
|
|
SRCL
11
DELISTED
Stericycle Inc
SRCL
| $149M | 4.29% |
+1,345,848
| New | +$146M |
|
12
Visa
V
$693B
| $144M | 4.16% |
+3,150,588
| New | +$138M |
|
|
VAR
13
DELISTED
Varian Medical Systems, Inc.
VAR
| $139M | 4.02% |
+2,353,407
| New | +$141M |
|
14
Verisk Analytics
VRSK
$24.4B
| $134M | 3.86% |
+2,236,306
| New | +$134M |
|
15
Gilead Sciences
GILD
$181B
| $126M | 3.64% |
+2,459,512
| New | +$128M |
|
16
Perrigo
PRGO
$1.98B
| $125M | 3.62% |
+1,036,502
| New | +$123M |
|
17
SLB Ltd
SLB
$79.9B
| $124M | 3.59% |
+1,734,079
| New | +$128M |
|
18
Booking.com
BKNG
$158B
| $122M | 3.54% |
+3,703,100
| New | +$113M |
|
19
NOV
NOV
$7.28B
| $104M | 3.01% |
+1,675,844
| New | +$103M |
|
20
American Express
AXP
$227B
| $96.2M | 2.78% |
+1,286,983
| New | +$91.6M |
|
21
Monster Beverage
MNST
$93.6B
| $93.2M | 2.69% |
+18,376,728
| New | +$86.3M |
|
Similar funds
David Rolfe's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for David Rolfe, which disclosed 21 positions worth $3.46B. Its ten largest holdings account for 61% of the portfolio.
Its largest position is Apple: 22,216,292 shares worth $315M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, followed by Financials and Healthcare.
- David Rolfe's largest Q2 2013 buy was Apple: 22,216,292 shares worth $315M.
- David Rolfe's ten largest holdings make up 61% of its $3.46B portfolio in Q2 2013.
- David Rolfe disclosed 21 positions in Q2 2013, its first 13F filing on record.
Based on Wedgewood Partners's 13F filing for Q2 2013, filed 16 Aug 2013.